Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

402 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Comparative study of esketamine and racemic ketamine in treatment-resistant depression: Protocol for a non-inferiority clinical trial.
Correia-Melo FS, Leal GC, Carvalho MS, Jesus-Nunes AP, Ferreira CBN, Vieira F, Magnavita G, Vale LAS, Mello RP, Nakahira C, Argolo FC, Cardoso T, Souza CDS, Fontes ATC, Ferreira MB, Araújo-de-Freitas L, Tuena MA, Echegaray MVF, Cavalcanti DE, Lucchese AC, Bandeira ID, Telles M, Lima CS, Sampaio AS, Silva SS, Marback RF, Del-Porto JA, Abreu JN, Sarin LM, Paixão CS, Carvalho LP, Machado PRL, Turecki G, Lacerda ALT, Quarantini LC. Correia-Melo FS, et al. Among authors: silva ss. Medicine (Baltimore). 2018 Sep;97(38):e12414. doi: 10.1097/MD.0000000000012414. Medicine (Baltimore). 2018. PMID: 30235716 Free PMC article. Clinical Trial.
Efficacy and safety of adjunctive therapy using esketamine or racemic ketamine for adult treatment-resistant depression: A randomized, double-blind, non-inferiority study.
Correia-Melo FS, Leal GC, Vieira F, Jesus-Nunes AP, Mello RP, Magnavita G, Caliman-Fontes AT, Echegaray MVF, Bandeira ID, Silva SS, Cavalcanti DE, Araújo-de-Freitas L, Sarin LM, Tuena MA, Nakahira C, Sampaio AS, Del-Porto JA, Turecki G, Loo C, Lacerda ALT, Quarantini LC. Correia-Melo FS, et al. Among authors: silva ss. J Affect Disord. 2020 Mar 1;264:527-534. doi: 10.1016/j.jad.2019.11.086. Epub 2019 Nov 14. J Affect Disord. 2020. PMID: 31786030 Clinical Trial.
Intravenous arketamine for treatment-resistant depression: open-label pilot study.
Leal GC, Bandeira ID, Correia-Melo FS, Telles M, Mello RP, Vieira F, Lima CS, Jesus-Nunes AP, Guerreiro-Costa LNF, Marback RF, Caliman-Fontes AT, Marques BLS, Bezerra MLO, Dias-Neto AL, Silva SS, Sampaio AS, Sanacora G, Turecki G, Loo C, Lacerda ALT, Quarantini LC. Leal GC, et al. Among authors: silva ss. Eur Arch Psychiatry Clin Neurosci. 2021 Apr;271(3):577-582. doi: 10.1007/s00406-020-01110-5. Epub 2020 Feb 20. Eur Arch Psychiatry Clin Neurosci. 2021. PMID: 32078034 Clinical Trial.
Ketamine and Esketamine augmentation for suicidal ideation: A randomized, double-blinded clinical trial.
Vieira F, Correia-Melo FS, Santos-Lima C, Souza-Marques B, Leal GC, Jesus-Nunes AP, Mello RP, Caliman-Fontes AT, Bandeira ID, Marback RF, Telles M, Argolo FC, Lins-Silva DH, Echegaray MVF, Beanes G, Araújo-de-Freitas L, Silva SS, Cardoso TA, Kapczinski F, Turecki G, Lacerda ALT, Quarantini LC. Vieira F, et al. Among authors: silva ss. Gen Hosp Psychiatry. 2021 Jan-Feb;68:97-99. doi: 10.1016/j.genhosppsych.2020.12.011. Epub 2020 Dec 20. Gen Hosp Psychiatry. 2021. PMID: 33376001 Clinical Trial. No abstract available.
Brain-derived neurotrophic factor serum levels following ketamine and esketamine intervention for treatment-resistant depression: secondary analysis from a randomized trial.
Caliman-Fontes AT, Leal GC, Correia-Melo FS, Paixão CS, Carvalho MS, Jesus-Nunes AP, Vieira F, Magnavita G, Bandeira ID, Mello RP, Beanes G, Silva SS, Echegaray M, Carvalho LP, Machado P, Sampaio AS, Cardoso TA, Kapczinski F, Lacerda ALT, Quarantini LC. Caliman-Fontes AT, et al. Among authors: silva ss. Trends Psychiatry Psychother. 2023;45:e20210298. doi: 10.47626/2237-6089-2021-0298. Epub 2023 Mar 7. Trends Psychiatry Psychother. 2023. PMID: 34904800 Free PMC article. Clinical Trial.
Letter to the Editor: Antidepressant and Antisuicidal Effects of Esketamine in Adolescents with Major Depressive Disorder and Suicidal Ideation: A Case Series.
Faria-Guimarães D, Vieira F, Souza-Marques B, Silva SS, Bandeira ID, Souza LS, Alves-Pereira R, Fontes M, Mello RP, Leal GC, Cardoso TA, Kapczinski F, Lacerda ALT, Sampaio AS, Quarantini LC. Faria-Guimarães D, et al. Among authors: silva ss. J Child Adolesc Psychopharmacol. 2022 Aug;32(6):366-367. doi: 10.1089/cap.2022.0013. Epub 2022 Jun 16. J Child Adolesc Psychopharmacol. 2022. PMID: 35708566 No abstract available.
Arketamine as adjunctive therapy for treatment-resistant depression: A placebo-controlled pilot study.
Leal GC, Souza-Marques B, Mello RP, Bandeira ID, Caliman-Fontes AT, Carneiro BA, Faria-Guimarães D, Guerreiro-Costa LNF, Jesus-Nunes AP, Silva SS, Lins-Silva DH, Fontes MA, Alves-Pereira R, Cordeiro V, Rugieri-Pacheco S, Santos-Lima C, Correia-Melo FS, Vieira F, Sanacora G, Lacerda ALT, Quarantini LC. Leal GC, et al. Among authors: silva ss. J Affect Disord. 2023 Jun 1;330:7-15. doi: 10.1016/j.jad.2023.02.151. Epub 2023 Mar 4. J Affect Disord. 2023. PMID: 36871913 Clinical Trial.
Arketamine for bipolar depression: Open-label, dose-escalation, pilot study.
Bandeira ID, Leal GC, Correia-Melo FS, Souza-Marques B, Silva SS, Lins-Silva DH, Mello RP, Vieira F, Dorea-Bandeira I, Faria-Guimarães D, Carneiro B, Caliman-Fontes AT, Kapczinski F, Miranda-Scippa Â, Lacerda ALT, Quarantini LC. Bandeira ID, et al. Among authors: silva ss. J Psychiatr Res. 2023 Aug;164:229-234. doi: 10.1016/j.jpsychires.2023.06.028. Epub 2023 Jun 23. J Psychiatr Res. 2023. PMID: 37385001 Clinical Trial.
402 results